USRE23705E - Diagnostic compositions - Google Patents
Diagnostic compositions Download PDFInfo
- Publication number
- USRE23705E USRE23705E US23705DE USRE23705E US RE23705 E USRE23705 E US RE23705E US 23705D E US23705D E US 23705DE US RE23705 E USRE23705 E US RE23705E
- Authority
- US
- United States
- Prior art keywords
- solid
- mixture
- urine
- cupric
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title description 66
- BERDEBHAJNAUOM-UHFFFAOYSA-N Copper(I) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 48
- 239000007787 solid Substances 0.000 description 30
- 229940112669 cuprous oxide Drugs 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 210000002700 Urine Anatomy 0.000 description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 239000004615 ingredient Substances 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 229910052783 alkali metal Inorganic materials 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 150000001720 carbohydrates Chemical class 0.000 description 12
- 235000014633 carbohydrates Nutrition 0.000 description 12
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 239000003513 alkali Substances 0.000 description 9
- 150000001340 alkali metals Chemical class 0.000 description 9
- 235000011121 sodium hydroxide Nutrition 0.000 description 9
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 9
- 229940077731 Carbohydrate nutrients Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- 235000002906 tartaric acid Nutrition 0.000 description 7
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000011975 tartaric acid Substances 0.000 description 6
- 229960001367 tartaric acid Drugs 0.000 description 6
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 5
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- 150000001342 alkaline earth metals Chemical class 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- ORTQZVOHEJQUHG-UHFFFAOYSA-L Copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 4
- 229940109239 Creatinine Drugs 0.000 description 4
- -1 alkali-metal tartrates Chemical class 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 235000011118 potassium hydroxide Nutrition 0.000 description 4
- 239000011973 solid acid Substances 0.000 description 4
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 125000000089 arabinosyl group Chemical class C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 150000004679 hydroxides Chemical class 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;hydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 229960001701 Chloroform Drugs 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L Copper(II) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- JJLJMEJHUUYSSY-UHFFFAOYSA-L Copper(II) hydroxide Chemical compound [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 description 2
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 2
- GYQBBRRVRKFJRG-UHFFFAOYSA-L Disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N Hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- FUJCRWPEOMXPAD-UHFFFAOYSA-N Lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 2
- 229960004011 Methenamine Drugs 0.000 description 2
- 210000004080 Milk Anatomy 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 229940048084 Pyrophosphate Drugs 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- 229940116269 Uric Acid Drugs 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 229960003280 cupric chloride Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000019820 disodium diphosphate Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000004312 hexamethylene tetramine Substances 0.000 description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910001947 lithium oxide Inorganic materials 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003638 reducing agent Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910001948 sodium oxide Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229960002737 Fructose Drugs 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000001893 Pentosuria Diseases 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J Tetrasodium pyrophosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 229910001451 bismuth ion Inorganic materials 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- PDZKZMQQDCHTNF-UHFFFAOYSA-M copper(1+);thiocyanate Chemical compound [Cu+].[S-]C#N PDZKZMQQDCHTNF-UHFFFAOYSA-M 0.000 description 1
- 229940076286 cupric acetate Drugs 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N dipotassium;oxygen(2-) Chemical class [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- VQNBUJAEBQLLKU-UHFFFAOYSA-H tricalcium;diphosphate;hydrate Chemical compound O.[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VQNBUJAEBQLLKU-UHFFFAOYSA-H 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
Definitions
- the present invention relates to diagnostic compositions and, more particularly, to diagnostic compositions suitable for the qualitative detection and quantitativeestimation of reducing carbohydrates (e. g., glucose, levulose, arabinose) in body fluids (e.'g., urine, cerebrospinal fluid, milk). It has for its object to provide a simple, rapid and convenient method for performing these-tests with a high degree of accuracy and without the necessity of employing an extraneous source of heat, such as a gas burner, alcohol lamp or ignited hexamethylenetetramine tablet.
- reducing carbohydrates e. g., glucose, levulose, arabinose
- body fluids e.'g., urine, cerebrospinal fluid, milk.
- the qualitative and quantitative estimations of glucose in urine are at present the best means available to the physician for controlling his diabetic patients.
- the daily dosage of insulin is usually determined by the presence or absence of glucose in the fasting urine, and, in the majority of diabetic patients, such a determination must be performed at least once daily. This is usually done by the patient himself.
- a member of the group of solid acids and acid reacting salts forming water-soluble complexes with cupric ions in alkaline solution which group consists of citric acid, tartaric acid, the alkali metal acid salts of citric [and tartaric acids, the alkali metal and alkaline-earth metal hemibasic and monobasic salts of orthophosphoric acid, and the alkali metal and alkaline-earth metal dibasic salts of pyrophosphoric] acid.
- the dry mixtures are tableted so that each tablet will be suflicient to make one diagnostic determination.
- these compositions either in powder or tablet form, are mixed with a small amount of an aqueous specimen such as urine, they dissolve rapidly with the evolution of a considerabl 1 amount of heat. It may be desirable to dilute the urine specimen with water. In the absence of a reducing carbohydrate, a clear blue solution is obtained. In the presence of a reducing sugar, a reen, yellow or brownish red precipitate of cuprous oxide is obtained, which is held in suspension by the highly concentrated alkaline solution. To determine quantitatively the amount of reducing carbohydrate present in the urine specimen, the color of the suspension may be compared with the panels of a standard color chart of known concentrations of glucose (or other reducing carbohydrates) in urine (or any other specimen being tested).
- the intensity of the observed color of the precipitate is directly proportional to the concentration of the colored substance (i. e., cuprous oxide).
- the concentration of the cuprous oxide is also directly proportional to the concentration of reducing carbohydrates originally present in the specimen, the observed color is likewise directly proportional to the concentration of the reducing substance.
- diluents, excipients, and ancillary or auxiliary agents may be incorporated into the dry diagnostic compositions.
- a minor proportion of an alkali metal bicarbonate e. g., sodium bicarbonate
- the dry diagnostic composition containing such a bicarbonate is added to the liquid specimen being tested, the solid acid or acid reacting salt therein will interact with the alkali metal bicarbonate liberating gaseous carbon dioxide.
- the effervescence thus produced serves to accelerate the mechanical disintegration of the composition, especially if it is in tablet form. The reaction is thus speeded up, and the determination is effected more promptly. Since the total heat evolution is thereby effected within a shorter period, there is less loss of heat by radiation, conduction and vaporization, and traces of reducing carbohydrates are detectable, which might otherwise go undetected.
- a desiccating agent such as calcium chloride, and diluents and excipients, such as kaolin and talc, may be employed without adversely affecting the sensitivity and specificity of the diagnostic compositions.
- diluents and excipients such as kaolin and talc
- auxiliary agents such as creatinine and the hydrophilic colloids, may be incorporated, their presence in the test solution being advised by Shei'tel, to prevent the formation of the red form of cuprous oxide.
- Typical examples of ingredients from group (a) above that may be used (i. e., water soluble cupric salts) in preparing the diagnostic compositions are cupric sulphate, cupric chloride, and cupric acetate.
- Typical examples of members of group (b) i. e., oxides and hydroxides of alkaline metals
- members of group (b) i. e., oxides and hydroxides of alkaline metals
- sodium hydroxide and potassium hydroxide are sodium hydroxide and potassium hydroxide.
- lithium oxide and hydroxide are more expensive than the other members of this group, their use in some compositions may be justified by reason of their comparatively low hygroscopicity.
- Sodium and potassium hydroxides are the preferred hydroxides since their heats of solution are more than double that of lithium hydroxide.
- sodium and potassium oxides both have considerably higher heats of solution than lithium oxide.
- Typical examples of ingredients of group (0) i. e., solid acids and acid reacting salts which form water soluble complexes with cupric ions in alkaline solution
- group (0) i. e., solid acids and acid reacting salts which form water soluble complexes with cupric ions in alkaline solution
- citric acid monohydrate
- tartaric acid and hemibasic sodium orthophosphate
- the following exampleljs] of a typical composition[s] covered by this invention [are] is intended to define and illustrate. but in no way to limit the invention to the particular reagents or proportions described therein. [These] This composition[s] may be used in the form of powder, or dispensed in pellets, or [they] it may be pressed into unitary reaction tablets of such a size as is convenient for the performance of a single test,
- Example [I] One kilogram of finely powdered caustic soda is thoroughly mixed with 500 grams of citric acid (monohydrate) and 50 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then pressed into five grain tablets.
- a tablet is placed into a testtube and 0.5 cc. of urine is added dropwise. A vigorous reaction occurs and the tablet dissolves in the urine with the evolution of considerable heat. In the presence of 0.075% or more of glucose in the urine, a suspension of cuprous oxide will be observed in the tube. The color of this suspension may be compared with that of a standard color chart to obtain an estimation of the amount of glucose present.
- the sensitivity of this composition is about 0.075% of glucose, 0.125% of lactose and 0.135% of arabinose.
- compositions are quite specific for reducing carbohydrates.
- chloroform, uric acid, creatinine and albumin do not interfere with this test as they do in the case of the Fehling test and the Nylander reaction.
- Example II [Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 200 grams of powdered anhydrous monobasic sodium orthophosphate and 20 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets] [To perform a test on a suspected urine, a tablet is dropped into a round bottomed test tube containing five drops of the urine and 10 drops of water. A vigorous reaction occurs and the tablet dissolves in the urine with the evolution of considerable heat. In the presence of 0.050% or more of glucose in the urine a suspension of cuprous oxide will be observed in the tube.
- the color of this suspension may be compared with that of the panels of a standard color chart to obtain an estimation of the amount of glucose present]
- the sensitivity of this composition is about 0.050% of glucose, 0.080% of lactose and 0.080% of arabinose.
- these compositions are quite specific for reducing carbohydrates. Chloroform, uric acid, creatinine and albumin do not interfere with this test, as they do in the case of the Fehling test and the Nylander reaction]
- Example 111 [Two kilograms of sixty mesh powdered caustic soda. are thoroughly mixed with 176 grams of powdered hemibasic sodium orthophosphate and 20 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tables] [These tablets are used in the manner described in Example II. The sensitivity and specificity are equally as good as those described in Example 11.]
- Example IV 7 [Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 180 grams of powdered dibasic sodium pyrophosphate (sodium acid pyrophosphate), 20 grams of powdered sodium bicarbonate and 20 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets, which are effervescent in use.]
- powdered dibasic sodium pyrophosphate sodium acid pyrophosphate
- sodium bicarbonate sodium bicarbonate
- cupric sulfate anhydrous cupric sulfate
- Example V [Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 200 grams of powdered anhydrous hemibasic calcium orthophosphate, 30 grams of sodium bicarbonate and 25 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets, which are eiiervescent] [Example VI] [Two kilograms of caustic potash chips are thoroughly mixed with 180 grams of monobasic calcium orthophosphate monohydrate crystals and 20 grams of anhydrous cupric chloride, until the mixture is homogeneous.
- Example VII [Two kilograms of anhydrous powdered lithium hydroxide are mixed with 250 grams of powdered monobasic potassium orthophosphate, 25 grams of sodium bicarbonate, 25 grams of anhydrous cupric sulfate and 50 grams of powdered talc, until the mixture is homogeneous.
- Example VIII [Two kilograms of powdered dibasic sodium acid pyrophosphate are thoroughly mixed with 700 grams of powdered sodium oxide (NazO) 20 grams of powdered sodium bicarbonate and 20 grams of anhydrous cupric sulfate, under the scrupulous exclusion of moisture, until the mix- L ture is homogeneous. It is then compressed into five grain unitary reaction tablets] Upon dissolution in water, the above composition is alkaline, and generates sufficient heat for the formation of cuprous oxide.
- NazO powdered sodium oxide
- anhydrous cupric sulfate yields more stable compositions than the hydrate salt[.]
- Anhydrous monobasic sodium orthophosphate is preferable to the hydrate]
- this [preference] greater stability holds for all of the ingredients having two forms of high and low (or no) water content.
- a hydrate does not have a tendency to deliquesce as the temperatures encountered in the localities where these compositions are to be used, it may be used in a. preparation of the present invention.
- Hemibasic sodium orthophosphate is particularly use ful in this connection, in that it forms no hydrate.
- the heat evolved during the reaction of the diagnostic compositions of this invention with urine, or similar specimens, is predominantly due to two exothermic reactions.
- One of these is the heat of solution of the'alkali metal oxide, or hydroxide, in the aqueous fluid.
- the other is the heat of neutralization of the solid acid or acid reacting salt with the alkali metal hydroxide in solution.
- the heat evolved will more than sufllce to efiect the reduction of the cupric complex to cuprous oxide, which forms a precipitate of characteristic color.
- the dry diagnostic compositions may be used for the qualitative detection and quantitative estimation of reducing carbohydrates other than glucose. Thus, they may be used to detect pentosuria, to estimate the amount of galactose in urine during a galactose tolerance test for [depatic] hepatic function or hyperthyroidism, or the amount of lactose in milk.
- a diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture said ingredients comprising essentially: a minor quantity of a water soluble solid cupric salt; a solid acidic material selected from the group consisting of citric acid, tartaric acid, an alkali metal acid salt of citric acid, [an alkali metal acid salt of tartaric acid, an alkali metal monobasic orthophosphate, an alkali metal dibasic pyrophosphate, an alkali metal hemibasic orthophosphate, an alkaline-earth metal monobasic orthophosphate, an alkaline-earth metal dibasic pyrophosphate, and an alkaline-earth metal hemi-basic orthophosphate;] and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali being present in excess of that
- a diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially a minor quantity of a water soluble solid cupric salt, a quantity of solid citric acid, and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess of that required to neutralize the solid citric acid in the mixture and in an amount adequate to generate suflicient heat to form said cuprous oxide.
- a diagnostic composition in solid dry form comprising a. mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially a minor quantity of a water soluble solid cupric salt, a quantity of solid tartaric acid, and
- a diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to'torm cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially a minor quantity of a water soluble solid cupric salt, a quantity of solid hemibasic sodium orthophosphate, and a quantity ofsolid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess or that required to neutralize the hemibasic sodium orthophosphate in the mixture, and in an amount adequate to generate suflicient heat to form said cuprous oxide] 5.
- a diagnostic composition in solid dry Iorm comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essen-- tially a minor quantity of solid cupric sulfate, a quantity of solid citric acid, and a quantity of solid sodium hydroxide, the latter being present in excess oi that required to neutralize the citric acid in the mixture and in an amount adequate to, generate sumcient. heat to form said cuprous oxide.
- a diagnostic composition in solid dry form comprising a mixture or ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material'supplied by the mixture, said ingredients comprising essentartaric acid in the mixture, and in an amount adequate to generate suflicient heat to form said cuprous oxide.
- a diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprisingessentially, a minor quantity of solid cupric suliate, a quantity of solid hemibasic sodium orthophosphate, and a quantity of solid sodium hydroxide, the latter being present in excess of that required to neutralize the hemibasic sodium orthophosphate in the mixture, and in an amount adequate to generate suflicient heat to form said cuprous oxide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Reissued Sept. 1 1953 23,105 DIAGNOSTIC COMPOSITIONS Jonas Kamlet, New York, N. Y., asslgnor to Miles Laboratories, Inc., Elkhart, Ind., a corporation of Indiana No Drawing. Original No. 2,418,033, dated March 25, 1947, Serial No. 701,403, October 5, 1946. Application for reissue July 1, 1953, Serial No.
5 Claims.
The present invention relates to diagnostic compositions and, more particularly, to diagnostic compositions suitable for the qualitative detection and quantitativeestimation of reducing carbohydrates (e. g., glucose, levulose, arabinose) in body fluids (e.'g., urine, cerebrospinal fluid, milk). It has for its object to provide a simple, rapid and convenient method for performing these-tests with a high degree of accuracy and without the necessity of employing an extraneous source of heat, such as a gas burner, alcohol lamp or ignited hexamethylenetetramine tablet.
The present application is a continuation-inpart of my copending applications, Serial No. 343,777 filed July 3, 1940, and Serial No. 500,558, filed August 30, 1943.
The qualitative and quantitative estimations of glucose in urine are at present the best means available to the physician for controlling his diabetic patients. The daily dosage of insulin is usually determined by the presence or absence of glucose in the fasting urine, and, in the majority of diabetic patients, such a determination must be performed at least once daily. This is usually done by the patient himself.
Methods heretofore available were based on the principle of heating a mixture of measured aliquots of urine and an alkaline copper solution (such as Benedict's, Fehling's, Folin-McEllroy) or an alkaline bismuth solution (such as Nylander, Almen). In qualitative estimations, the precipitation of cuprous oxide from the cupric compound, in the former case, or the reduction of the bismuth ion to black metallic bismuth, in the latter case, would indicate the presence of a reducing carbohydrate.
In quantative estimations, the usual method employed heretofore has been that of Benedict (Journa1 of the American Medical Association, vol. 57, page 1193, 1911). This involves adding measured amounts of urine to an aliquot of a standard solution, while boiling the latter, until the blue cupric compound contained therein is completely decolorized, forming cuprous thiocyanate. By a calculation, the percentage of reducing substance in the urine is determined.
Sheitel, United States Patent No. l,769,862, has described a method for the quantitative determination of sugar in urine based on the following steps: (a) Measured aliquots of a special modifled Benedict solution containing creatinine and a hydrophile colloid are mixed with a measured aliquot of urine; (b) the mixture is heated in boiling water for five minutes; (c) if a change in the original blue color appears, the solution Matter enclosed in heavy brackets appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue.
is compared with a color scale and the corresponding percentage of sugar is estimated.
All of the procedures thus mentioned have one great drawback. They all require an extraneous source of heat. It 'is obvious that a diabetic going about his daily business, or a military physician in the field, or a physician at his patients bedside, cannot always have a gas burner available. Attempts to heat water by igniting hexamethylenetetramine tablets are usually futile.
Since the reduction of cupric ions to the cuprous form by glucose is eil'ected only at advanced temperatures, it is the further purpose of this invention to provide dry, solid, alkaline, cupric ionccntaining, compositions which will dissolve in urine with a strongly exothermic reaction, and which will be reduced to cuprous oxide if glucose or any other reducing carbohydrate is present in the urine. This will be efiected without recourse to any extraneous source of heat.
The basis of all diagnostic solutions containing alkaline cupric ions heretofore employed is: (a) a cupric salt, such as cupric sulfate; (b) an alkaline-reacting substance, such as sodium carbonate, or potassium hydroxide; (c) a member of the group of normal salts that are capable of holding cupric hydroxide in solution. Fehling (Annalen, vol. 72, page 106, of 1849) used normal alkali-metal tartrates (Rochelle salts), while Benedict (J. Biol. Chem. vol. 3, page 101, of 1907) used normal alkali-metal citrates and Folin- McEllroy (J. Biol. Chem. vol. 33, page 513, of 1918) used normal alkali-metal phosphates, Pyrophosphates and thiocyanates.
I have found that stable diagnostic compositions of excellent specificity for reducing carbohydrates, and fulfilling the objects of the present invention, may be obtained by preparing solid, dry mixtures of the following ingredients in proper proportions:
(a) A water soluble cupric salt.
(b) A solid alkali material of the group consisting of the oxides and hydroxides of the alkali metals, and
(c) A member of the group of solid acids and acid reacting salts forming water-soluble complexes with cupric ions in alkaline solution, which group consists of citric acid, tartaric acid, the alkali metal acid salts of citric [and tartaric acids, the alkali metal and alkaline-earth metal hemibasic and monobasic salts of orthophosphoric acid, and the alkali metal and alkaline-earth metal dibasic salts of pyrophosphoric] acid.
Preferably, for convenience of the user, the dry mixtures are tableted so that each tablet will be suflicient to make one diagnostic determination. When these compositions, either in powder or tablet form, are mixed with a small amount of an aqueous specimen such as urine, they dissolve rapidly with the evolution of a considerabl 1 amount of heat. It may be desirable to dilute the urine specimen with water. In the absence of a reducing carbohydrate, a clear blue solution is obtained. In the presence of a reducing sugar, a reen, yellow or brownish red precipitate of cuprous oxide is obtained, which is held in suspension by the highly concentrated alkaline solution. To determine quantitatively the amount of reducing carbohydrate present in the urine specimen, the color of the suspension may be compared with the panels of a standard color chart of known concentrations of glucose (or other reducing carbohydrates) in urine (or any other specimen being tested).
In accordance with Beers law, on which the entire art of colorimetry is based, the intensity of the observed color of the precipitate is directly proportional to the concentration of the colored substance (i. e., cuprous oxide). However, since the concentration of the cuprous oxide is also directly proportional to the concentration of reducing carbohydrates originally present in the specimen, the observed color is likewise directly proportional to the concentration of the reducing substance.
If desired, diluents, excipients, and ancillary or auxiliary agents may be incorporated into the dry diagnostic compositions. Thus, a minor proportion of an alkali metal bicarbonate (e. g., sodium bicarbonate) may be added. When the dry diagnostic composition containing such a bicarbonate is added to the liquid specimen being tested, the solid acid or acid reacting salt therein will interact with the alkali metal bicarbonate liberating gaseous carbon dioxide. The effervescence thus produced serves to accelerate the mechanical disintegration of the composition, especially if it is in tablet form. The reaction is thus speeded up, and the determination is effected more promptly. Since the total heat evolution is thereby effected within a shorter period, there is less loss of heat by radiation, conduction and vaporization, and traces of reducing carbohydrates are detectable, which might otherwise go undetected.
A desiccating agent, such as calcium chloride, and diluents and excipients, such as kaolin and talc, may be employed without adversely affecting the sensitivity and specificity of the diagnostic compositions. Auxiliary agents, such as creatinine and the hydrophilic colloids, may be incorporated, their presence in the test solution being advised by Shei'tel, to prevent the formation of the red form of cuprous oxide.
Typical examples of ingredients from group (a) above that may be used (i. e., water soluble cupric salts) in preparing the diagnostic compositions are cupric sulphate, cupric chloride, and cupric acetate.
Typical examples of members of group (b) (i. e., oxides and hydroxides of alkaline metals) that may be used in the diagnostic compositions are sodium hydroxide and potassium hydroxide. Although lithium oxide and hydroxide are more expensive than the other members of this group, their use in some compositions may be justified by reason of their comparatively low hygroscopicity. Sodium and potassium hydroxides are the preferred hydroxides since their heats of solution are more than double that of lithium hydroxide. Likewise, sodium and potassium oxides both have considerably higher heats of solution than lithium oxide.
Typical examples of ingredients of group (0) (i. e., solid acids and acid reacting salts which form water soluble complexes with cupric ions in alkaline solution) that may be used in preparing the dry diagnostic compositions are: citric acid (monohydrate) and, tartaric acid [and hemibasic sodium orthophosphate The following exampleljs] of a typical composition[s] covered by this invention [are] is intended to define and illustrate. but in no way to limit the invention to the particular reagents or proportions described therein. [These] This composition[s] may be used in the form of powder, or dispensed in pellets, or [they] it may be pressed into unitary reaction tablets of such a size as is convenient for the performance of a single test,
Example [I] One kilogram of finely powdered caustic soda is thoroughly mixed with 500 grams of citric acid (monohydrate) and 50 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then pressed into five grain tablets.
To perform a test, a tablet is placed into a testtube and 0.5 cc. of urine is added dropwise. A vigorous reaction occurs and the tablet dissolves in the urine with the evolution of considerable heat. In the presence of 0.075% or more of glucose in the urine, a suspension of cuprous oxide will be observed in the tube. The color of this suspension may be compared with that of a standard color chart to obtain an estimation of the amount of glucose present.
The sensitivity of this composition is about 0.075% of glucose, 0.125% of lactose and 0.135% of arabinose.
Similarly, these compositions are quite specific for reducing carbohydrates. chloroform, uric acid, creatinine and albumin do not interfere with this test as they do in the case of the Fehling test and the Nylander reaction.
[Example II] [Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 200 grams of powdered anhydrous monobasic sodium orthophosphate and 20 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets] [To perform a test on a suspected urine, a tablet is dropped into a round bottomed test tube containing five drops of the urine and 10 drops of water. A vigorous reaction occurs and the tablet dissolves in the urine with the evolution of considerable heat. In the presence of 0.050% or more of glucose in the urine a suspension of cuprous oxide will be observed in the tube. The color of this suspension may be compared with that of the panels of a standard color chart to obtain an estimation of the amount of glucose present] [The sensitivity of this composition is about 0.050% of glucose, 0.080% of lactose and 0.080% of arabinose. Similarly, these compositions are quite specific for reducing carbohydrates. Chloroform, uric acid, creatinine and albumin do not interfere with this test, as they do in the case of the Fehling test and the Nylander reaction] [Example 111] [Two kilograms of sixty mesh powdered caustic soda. are thoroughly mixed with 176 grams of powdered hemibasic sodium orthophosphate and 20 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tables] [These tablets are used in the manner described in Example II. The sensitivity and specificity are equally as good as those described in Example 11.]
[Example IV] 7 [Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 180 grams of powdered dibasic sodium pyrophosphate (sodium acid pyrophosphate), 20 grams of powdered sodium bicarbonate and 20 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets, which are effervescent in use.]
[These tablets are used in the manner described in Example I. The sensitivity and specificity are equally as good as those described in Example 1.]
[Example V] [Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 200 grams of powdered anhydrous hemibasic calcium orthophosphate, 30 grams of sodium bicarbonate and 25 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets, which are eiiervescent] [Example VI] [Two kilograms of caustic potash chips are thoroughly mixed with 180 grams of monobasic calcium orthophosphate monohydrate crystals and 20 grams of anhydrous cupric chloride, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets] [Example VII] [Two kilograms of anhydrous powdered lithium hydroxide are mixed with 250 grams of powdered monobasic potassium orthophosphate, 25 grams of sodium bicarbonate, 25 grams of anhydrous cupric sulfate and 50 grams of powdered talc, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets] [Example VIII] [Two kilograms of powdered dibasic sodium acid pyrophosphate are thoroughly mixed with 700 grams of powdered sodium oxide (NazO) 20 grams of powdered sodium bicarbonate and 20 grams of anhydrous cupric sulfate, under the scrupulous exclusion of moisture, until the mix- L ture is homogeneous. It is then compressed into five grain unitary reaction tablets] Upon dissolution in water, the above composition is alkaline, and generates sufficient heat for the formation of cuprous oxide.
Because of the hygroscopicity of compositions within the scope of this invention, it is desirable, although by no means imperative, to use anhydrous reagents instead of the corresponding hydrates. Thus anhydrous cupric sulfate yields more stable compositions than the hydrate salt[.] [Anhydrous monobasic sodium orthophosphate is preferable to the hydrate], and this [preference] greater stability holds for all of the ingredients having two forms of high and low (or no) water content. However, if a hydrate does not have a tendency to deliquesce as the temperatures encountered in the localities where these compositions are to be used, it may be used in a. preparation of the present invention. [Hemibasic sodium orthophosphate is particularly use ful in this connection, in that it forms no hydrate.]
The heat evolved during the reaction of the diagnostic compositions of this invention with urine, or similar specimens, is predominantly due to two exothermic reactions. One of these is the heat of solution of the'alkali metal oxide, or hydroxide, in the aqueous fluid. The other is the heat of neutralization of the solid acid or acid reacting salt with the alkali metal hydroxide in solution. The heat evolved will more than sufllce to efiect the reduction of the cupric complex to cuprous oxide, which forms a precipitate of characteristic color.
The dry diagnostic compositions may be used for the qualitative detection and quantitative estimation of reducing carbohydrates other than glucose. Thus, they may be used to detect pentosuria, to estimate the amount of galactose in urine during a galactose tolerance test for [depatic] hepatic function or hyperthyroidism, or the amount of lactose in milk.
I claim:
1. A diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture said ingredients comprising essentially: a minor quantity of a water soluble solid cupric salt; a solid acidic material selected from the group consisting of citric acid, tartaric acid, an alkali metal acid salt of citric acid, [an alkali metal acid salt of tartaric acid, an alkali metal monobasic orthophosphate, an alkali metal dibasic pyrophosphate, an alkali metal hemibasic orthophosphate, an alkaline-earth metal monobasic orthophosphate, an alkaline-earth metal dibasic pyrophosphate, and an alkaline-earth metal hemi-basic orthophosphate;] and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali being present in excess of that required to neutralize the solid acidic material in the mixture and in an amount adequate to generate suflicient heat to form said cuprous oxide.
2. A diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially a minor quantity of a water soluble solid cupric salt, a quantity of solid citric acid, and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess of that required to neutralize the solid citric acid in the mixture and in an amount adequate to generate suflicient heat to form said cuprous oxide.
3. A diagnostic composition in solid dry form comprising a. mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially a minor quantity of a water soluble solid cupric salt, a quantity of solid tartaric acid, and
a quantity of solid alkali material selected from the group consisting or alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess of that required to neutralize the solid tartaric acid in the mixture and in an amount adequate to generate sufllcient heat I to form said cuprous oxide.
[4. A diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to'torm cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially a minor quantity of a water soluble solid cupric salt, a quantity of solid hemibasic sodium orthophosphate, and a quantity ofsolid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess or that required to neutralize the hemibasic sodium orthophosphate in the mixture, and in an amount adequate to generate suflicient heat to form said cuprous oxide] 5. A diagnostic composition in solid dry Iorm comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essen-- tially a minor quantity of solid cupric sulfate, a quantity of solid citric acid, and a quantity of solid sodium hydroxide, the latter being present in excess oi that required to neutralize the citric acid in the mixture and in an amount adequate to, generate sumcient. heat to form said cuprous oxide.
6. A diagnostic composition in solid dry form comprising a mixture or ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material'supplied by the mixture, said ingredients comprising essentartaric acid in the mixture, and in an amount adequate to generate suflicient heat to form said cuprous oxide.
[7. A diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprisingessentially, a minor quantity of solid cupric suliate, a quantity of solid hemibasic sodium orthophosphate, and a quantity of solid sodium hydroxide, the latter being present in excess of that required to neutralize the hemibasic sodium orthophosphate in the mixture, and in an amount adequate to generate suflicient heat to form said cuprous oxide] MILES LABORATORIES, INC. By WALTER A. COMPTON, Vice President.
No references cited.
Publications (1)
Publication Number | Publication Date |
---|---|
USRE23705E true USRE23705E (en) | 1953-09-01 |
Family
ID=2091233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US23705D Expired USRE23705E (en) | Diagnostic compositions |
Country Status (1)
Country | Link |
---|---|
US (1) | USRE23705E (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2787597A (en) * | 1953-12-16 | 1957-04-02 | Shinohara Kamenosuke | Process for determining sugar content in blood |
US2964165A (en) * | 1956-11-13 | 1960-12-13 | Chempel Inc | Corrosion resistant aerosol package containing hydrolyzable material |
-
0
- US US23705D patent/USRE23705E/en not_active Expired
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2787597A (en) * | 1953-12-16 | 1957-04-02 | Shinohara Kamenosuke | Process for determining sugar content in blood |
US2964165A (en) * | 1956-11-13 | 1960-12-13 | Chempel Inc | Corrosion resistant aerosol package containing hydrolyzable material |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fujiwara et al. | Determination of thiamine by thiochrome reaction | |
Masato | An improved method for determination of L-ascorbic acid and L-dehydroascorbic acid in blood plasma | |
Kingsley et al. | Microdetermination of arsenic and its application to biological material | |
Carlson et al. | Spectrophotometric determination of silicon | |
US3447904A (en) | Test indicator for the detection of chlorides | |
US2418033A (en) | Diagnostic compositions | |
US2283262A (en) | Diagnostic composition and method | |
US2577978A (en) | Diagnostic composition | |
Gardner et al. | Abnormal membrane sodium transport in Liddle's syndrome | |
USRE23705E (en) | Diagnostic compositions | |
US3266868A (en) | Diagnostic composition and test indicator | |
Ingols et al. | Urea hydrolysis for precipitating calcium oxalate | |
US3121613A (en) | Calcium determination method | |
US3164534A (en) | Diagnostic composition | |
US3310382A (en) | Biuret reagent | |
Hohnstedt et al. | Aqueous Sodium Borohydride Chemistry. The Colnage Metals, Copper, Silver, and Gold. | |
CN104101576A (en) | Method for determining nickel content in steel or iron alloy | |
US3630958A (en) | Test composition and method for detecting reducing sugars in aqueous fluids | |
US2865718A (en) | Urine sugar testing | |
US3425805A (en) | Phosphite testing method | |
US2608533A (en) | Composition and method for testing biological fluids | |
US2824842A (en) | Urine calcium test | |
US4840914A (en) | Gender-indicating colormetric test on pregnancy urine and test kit therefor | |
Derr et al. | Complex Ions. II. The Stability and Activity Coefficients of the Silver-Ammonia Ion1 | |
US1543961A (en) | Reagent |